TK1

REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatmentAdditional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatmentPlans to continue monotherapy dose escalation and initiate combination studies in 1H 2025 SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. These results were presented today after market close at an AACR Special Conference in Cancer Research. The company will also hold a webinar on December 10 at 6:30 AM MT / 8:30 AM ET / 1:30 PM GMT to present the preliminary data broadcast from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts with an opportunity to submit questions here. "Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers," said David Hallett, Ph.D., Chief Scientific Officer of Recursion. "By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index. Using our precision design platform, we created a molecule with rapid oral absorption to reduce GI tissue exposure, a suitable half life to manage side effects, and target engagement covering the IC80 level." ELUCIDATE is an ongoing Phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) of REC-617 in patients with advanced solid tumors. As of the November 15, 2024 data cutoff, preliminary findings include 18 patients with advanced solid tumors who were response evaluable in the monotherapy dose-escalation phase. Doses ranged from 2 mg to 20 mg once daily (QD) and 1 mg twice daily (BID). REC-617 was generally well-tolerated across all dose levels, with no discontinuations due to adverse events (AEs). Adverse events to date were predominately Grade 1-2, on-target, and reversible. An MTD has not yet been reached. While efficacy was not an endpoint in this Phase 1 study, or anticipated in monotherapy, a confirmed durable partial response (PR) by RECIST on REC-617 monotherapy was achieved in a patient with metastatic, platinum-resistant ovarian cancer. The response is on-going after more than 6 months of treatment. This patient had progressed following 4 lines of prior therapy in the advanced setting. In addition, four patients achieved a best response of stable disease (SD) across multiple dose levels for up to 6 months of treatment. "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer, Recursion. "Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." In parallel to the ongoing monotherapy dose escalation (QD and BID), combination studies are expected to initiate for ELUCIDATE in H1, 2025. The company expects to present additional ELUCIDATE as well as preclinical REC-617 data at future medical meetings. Summary of Interim REC-617 Monotherapy Dose Escalation Results Study Design & Demographics Phase 1 monotherapy dose escalation in advanced solid tumorsData cutoff as of November 15, 2024 - 19 patients enrolled (18 response evaluable)Heavily pre-treated population (median of 4 prior lines of therapy in the advanced setting)Antiemetics and anti-diarrheals not mandated prophylaxis for nausea/vomiting/diarrhea PK/PD Summary REC-617 exceeds CDK7 IC80 with rapid absorption (Tmax 0.5–2 hours) with a half-life of 5-6 hoursEarly POLR2A 3-4x modulation suggests ~80–90% target engagementQuick, time-limited target engagement with POLR2A normalization in 24 hoursTwice-daily (BID) dosing under investigation Safety Profile/AE Summary Adverse events (AEs) were predominantly low grade, on-target, and reversible upon treatment cessationEarly data indicates a favorable safety profile – maximum tolerated dose (MTD) not reachedNo treatment discontinuations due to AEs3 treatment related serious adverse events (SAE)s reported in 2/19 patientsEvents resolved and treatment continued after dose reductionAntiemetics and anti-diarrheals not mandated prophylaxis for nausea/vomiting/diarrhea Confirmed Partial Response & Stable Disease Summary One confirmed partial response (PR) by RECIST 1.1 (decrease of more than 30% in the sum of the longest diameters of target lesions + no new lesions + no progression of non target lesions) Partial response (-34%) achieved with reduction of 2 lymph nodes (para-aortic and mesenteric) at Week 16 with normalization of LDHReduction of tumor marker CA125 from 1249 to 694 kU/L (-44%)Reduction of tumor marker TK1 from 174 to 56 DuA (-68%)Response ongoing after more than 6 months of treatmentPatient continues study therapy without need for antiemetics Four additional patients achieved durable (up to 6 months of treatment) response of stable disease (SD) as best response across multiple dose levels All four patients progressed prior to entering the studyThree CRC patients (6L-7L) and one NSCLC patient (4L)One patient on 2mg QD and three patients on 10mg QD About REC-617REC-617 is a potential best-in-class CDK7 inhibitor, precision designed using AI-led approaches, with only 136 novel molecule synthesized from hit to candidate identification in less than 12 months. The molecule is designed to maximize its therapeutic index by enabling the tight control of both the extent and duration of target inhibition. CDK7 inhibition combines many potential benefits such as transcription inhibition, reduction of aberrant kinome activation, cell cycle inhibition, and modulation of estrogen receptor activity. This makes it an attractive target to overcome common resistance pathways associated with CDK4/6 inhibition, which only targets the cell cycle. About ELUCIDATEREC-617 is currently being evaluated as a monotherapy in the ELUCIDATE trial. ELUCIDATE is a multicenter, open-label, two-stage clinical trial to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy of REC-617 in advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, head and neck cancer. Both the monotherapy and combination therapy dose escalation portion of the trial will enroll patients across multiple dose levels to determine the optimal biological dose (OBD). The dose expansion phase of the trial will commence upon identification of the OBD. The primary efficacy endpoint of the expansion phase is objective response rate (ORR). About RecursionRecursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn. Media ContactMedia@Recursion.com Investor ContactInvestor@Recursion.com Forward-Looking Statements This document contains information that includes or is based upon “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding the potential efficacy of REC-617; timing of the Phase 1/2 clinical trial of REC-617; early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

UPPSALA, SE / ACCESSWIRE / November 26, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, announces that seven abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest breast cancer meeting, San Antonio Breast Cancer Symposium (SABCS) on December 10-13, 2024. Two of the abstracts validates DiviTum TKa in the adjuvant setting (early breast cancer), which will open a new market opportunity for Biovica, increasing the addressable market within breast cancer with $3BUSD / year on key markets (US, Europe and Japan).The new data reinforce DiviTum TKa as a monitoring and predictive test for hormone receptor-positive (HR+) patients with both metastatic and early breast cancer (adjuvant) treated with CDK4/6 inhibitors, the most prescribed drug class for this patient population."The SABCS-symposium is an excellent opportunity to share the great results achieved in clinical trials with DiviTum TKa and provides exposure to around 11,000 participants. This year with a record of seven abstracts. We are also very excited about the strong adjuvant (early breast cancer) data, indicating a vast market opportunity for us plus the possibility to improve care for even more breast cancer patients," said Anders Rylander, CEO of Biovica.More about theAbstract TitleInstitutionPatient PopulationKey Findings"Interrogating serum thymidine kinase activity with CDK4/6 inhibitor-based therapies: real-world experience in the metastatic and adjuvant setting."Roswell Park, USHR+ MBC 1ST LINE HR+ ADJUVANT BC ABEMATKa is predictive in adjuvant BC • An on therapy TKa level of <50 DuA is predictive for a >20 month response to therapy in CDK4/6i treated pts diagnosed with HR+ MBC• An on-therapy TKa level of >243 is predictive for <8 months of response to therapy• Adjuvant BC pts treated with abemaciclib had a highly significant reduction in TKa between BL and C1/C2• Elevated TKa levels were observed with disease recurrence"Evaluation of proliferation biomarker serum thymidine kinase activity and prediction of early relapse in HR-positive HER2 negative high-risk early breast cancer: Analysis from the PENELOPE-B trial."The German Breast Cancer Group, Germany, and USHR+ ADJUVANT BC PALBOTKa is prognostic in adjuvant BC• In PENELOPE-B, BL TKa values >250 DuA were prognostic for early relapse within the 1st year of adjuvant therapy• CPS-EG scores, in contrast, were not prognostic. • Pts with early disease relapse also had an increase in TKa levels at the time of recurrence."ctDNA and serum thymidine kinase activity as tools to stratify ER+/HER2- metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibitors: preliminary results of the TIRESIAS trial."Hospital of Prato, ItalyHR+ MBC 1ST LINETKa offers an attractive alternative to ctDNA • Circulating tumor DNA (ctDNA) and thymidine kinase activity (TKa) give complimentary information• TKa and ctDNA dynamic changes are concordant • TKa offers a cost-effective and easier alternative to ctDNA for non-invasive monitoring of early response to therapy"Thymidine kinase activity as a prognostic biomarker for first-line CDK4/6 inhibitor efficacy in the Personalised Disease Monitoring in Metastatic Breast Cancer (PDM-MBC) Study."Jönköping Hospital Sweden, Christie in Manchester, UKHR+ MBC 1ST LINETKa levels are prognostic for CDK4/6i efficacy in HR+ MBC• Baseline (BL) TKa >250 DuA associated with shorter PFS (13.5 mo vs not reached) and OS (30.3 vs 51.8 mo) in 1st line CDK4/6 inhibitor pts• A TKa value >100 DuA at any cycle 1 timepoint (BL, D15, D28) predicted for a significantly worse PFS and OS vs staying below 100 DuA at all 3 timepoints."The Role of Serum Thymidine Kinase 1 (TK1) as a Prognostic Factor in Luminal HER2 Negative Breast Cancer."IRBLeida, SpainHR+ Early breast cancer pre/post surgeryHR+ MBC 1ST LINETKa is a prognostic biomarker in luminal BC• EBC pts with high TKa also have a high OncotypeDx score. • MBC pts who had an on-therapy increase in TKa had progression in 3-6 mo• MBC pts who had an on-therapy decrease in TKa had a response lasting greater than 3-6 mo"Thymidine kinase activity as a prognostic and predictive biomarker in the Phase II PACE trial of CDK4/6 inhibition beyond progression ."Dana Farber Cancer Institute, USHR+ MBC 2ND LINE - PALBOTKa can predict 2nd line CDK4/6i benefit• There currently is no existing biomarker to predict the benefit to a CDK4/6i following progression on a previous CDK4/6i• High C2D1 on-treatment TKa (>250 DuA) was associated with a lack of response to palbociclib beyond progression on a prior CDK4/6i• Authors conclude TKa could facilitate clinical decisions in this context"Thymidine kinase activity as a predictive biomarker for benefit to a second line CDK4/6 inhibitor: analysis from the MAINTAIN trial.Emory, USHR+ MBC 2ND LINE RIBOTKa can predict 2nd line CDK4/6i benefit• TKa levels on C2D1 significantly predicted for the benefit to ribociclib after progression on a prior CDK4/6i• TKa <250 DuA had a PFS of 10.9 mo on ribociclib• TKa >250 DuA had a PFS of 2.7 mo on ribociclibList of abbreviationsABEMA The CDK4/6 inhibitor from Eli Lilly called AbemaciclibBC Breast CancerBL Base Line - prior to treatmentC1 treatment cycle 1C2 treatment cycle 2C2/D1 treatment cycle 2, day 1CDK4/6i CDK4/6 inhibitor treatmentsCPS-EG score: The CPS (Clinical and Pathological Score) + EG (Estrogen and Grade) scoring systemctDNA circulating tumor DNAD15 Day 15D28 Day 28DuA DiviTum units of activityEBC early breast cancerHER2 Human Epidermal growth factor Receptor 2HR Hormone receptorHR+ Hormone receptor-positiveMBC Metastatic breast cancermo monthsOS overall survivalPALBO The CDK4/6 inhibitor from Pfizer called PalbociclibPFS progression-free survivalPts PatientsRIBO The CDK4/6 inhibitor from Novartis called RibociclibTKa Thymidine Kinase activityContactAnders Rylander, CEOPhone: +46 76 666 16 47E-mail: [email protected]Anders Morén, CFOPhone: +46 73 125 92 46E-mail: [email protected]Biovica - Treatment decisions with greater confidenceBiovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: www.biovica.comThis information is information that Biovica International is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-26 08:00 CET.AttachmentsNew DiviTum® TKa data to be presented at SABCS that significantly broaden the addressable marketSOURCE: Biovica International

-- Updated Phase 1 dose escalation data show that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting toxicities -- -- Early signal of clinical activity includes compelling biomarker reductions correlated with BLU-222 exposure -- CAMBRIDGE, Mass., May 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical trial of BLU-222, an investigational, highly selective and potent CDK2 inhibitor, in combination with ribociclib and fulvestrant in patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer. The data, which mark the first promising clinical results for a CDK2 inhibitor in combination with an approved CDK4/6 inhibitor, will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2024. "At ASCO, we will present highly encouraging clinical data showing that our selective CDK2 inhibitor BLU-222, in combination with ribociclib, a standard of care CDK4/6 inhibitor for HR+ breast cancer, is very well-tolerated and delivers early evidence of clinical activity. This represents a highly significant milestone and holds promise as an important new cornerstone for the treatment of breast cancer, including in the front-line metastatic setting," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "These data validate the potency and selectivity of BLU-222, its potential as a first- and best-in-class CDK2 inhibitor, and its use as the combination partner of choice in breast cancer. With these data in hand, we are advancing ongoing partnering discussions that aim to accelerate development of BLU-222 into registration-directed clinical trials." Updated Phase 1/2 VELA Trial Results Based on previously reported positive BLU-222 monotherapy clinical data, a combination dose escalation arm was initiated in the VELA trial to assess the safety and clinical activity of BLU-222 in combination with ribociclib, a CDK4/6 inhibitor approved by the U.S. Food and Drug Administration for advanced or metastatic HR+/HER2- breast cancer, and fulvestrant, a commonly used estrogen receptor antagonist. As of the data cutoff date, 19 patients with HR+/HER2- breast cancer who had progressed on prior CDK4/6 inhibitors were treated with 100 mg to 400 mg twice daily (BID) of BLU-222 plus 400 mg once daily (QD) of ribociclib and combined with fulvestrant. The combination of BLU-222, ribociclib, and fulvestrant was well-tolerated at all BLU-222 dose levels tested. No dose-limiting toxicities, treatment-related severe adverse events (SAEs), or BLU-222-related treatment discontinuations were reported. Treatment-related hematologic and gastrointestinal AEs were generally mild. The maximum tolerated combination dose has not been identified, and combination dose escalation is ongoing. Pharmacokinetic data showed dose-proportional exposures of BLU-222, with sustained coverage above the predicted efficacious concentration at the 400 mg BID dose level. In addition, the combination of BLU-222 with ribociclib and fulvestrant had no clinically meaningful impact on individual drug exposures. Preliminary clinical activity showed compelling reductions in thymidine kinase 1 (TK1) and circulating tumor DNA (ctDNA), biomarkers that have been shown to be predictive of clinical benefit. TK1, a biomarker of tumor proliferation, had the deepest reduction among patients treated with BLU-222 400 mg BID, ribociclib 400 mg QD, and combined with fulvestrant, and was statistically significantly correlated with BLU-222 exposure. All patients with evaluable ctDNA, a biomarker of tumor burden, treated with the BLU-222 400 mg BID combination dose regimen showed ctDNA reductions. Early evidence of clinical benefit includes an unconfirmed partial response in a patient who had previously progressed following six lines of therapy in the metastatic setting, including prior palbociclib and trastuzumab deruxtecan. These data highlight the impact of CDK2 inhibition when BLU-222 is combined with other therapies. Detailed data will be presented by Dr. Dejan Duric from the Henri and Belinda Termeer Center for Targeted Therapies at Massachusetts General Hospital on June 2, 2024, during the "Breast Cancer – Metastatic" poster session at 9:00 a.m. CT. At the time of presentation, a copy of the poster will be available in the "Science—Publications and Presentations" section of the company's website at . About BLU-222 BLU-222 is a highly selective and potent investigational CDK2 inhibitor with first- and best-in-class potential, designed by scientists at Blueprint Medicines. CDK2 is a cell cycle regulator and an important cancer target, with relevance in HR+/HER2- breast cancer and other malignancies, such as subsets of ovarian and endometrial cancer. Across multiple cancer types, aberrant CCNE1 hyperactivates CDK2, resulting in cell cycle dysregulation and tumor proliferation. Aberrant CCNE1 has been observed as a primary driver of disease, as well as a mechanism of resistance to CDK4/6 inhibitors. In HR+/HER2- breast cancer, the advent of CDK4/6 inhibitors has improved treatment; however, disease progression is nearly universal, and new innovation is needed to improve outcomes and prolong clinical benefit. Historically, CDK2 inhibitor development by others has been challenged due to poor selectivity limiting tolerability and combination potential. Beyond BLU-222, Blueprint Medicines is advancing additional preclinical therapeutic candidates for cell cycle targets including BLU-956, a next-generation CDK2 inhibitor, a CDK2 targeted protein degradation program, and an additional undisclosed research program. About Blueprint Medicines Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation: statements regarding plans, strategies, timelines and expectations for Blueprint Medicines' operations, including its expectations for our current or future approved drugs and drug candidates, including BLU-222; the development of BLU-222 and whether it has first-and best-in-class potential; the potential benefits of any of our current or future approved drugs or drug candidates in treating patients, including the potential benefits of BLU-222 in combination with ribociclib and fulvestrant in patients with HR+/HER2- breast cancer; and the potential to partner with a third party to accelerate development of BLU-222 into registration-directed clinical trials. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to: the delay of any current or planned clinical trials or the development of the company's current or future drug candidates; the company's ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the possibility that preclinical and clinical results for the company's drug candidates may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; the timing of the initiation of clinical trials and trial cohorts at clinical trial sites and the possibility patient enrollment rates may be delayed or slower than anticipated; the actions of regulatory agencies and how this may affect the initiation, timing and progress of clinical trials; the company's ability to obtain, maintain and enforce patent and other intellectual property protection for its products and current or future drug candidates it is developing; and the success of the company's current and future collaborations, partnerships or licensing arrangements. Any forward-looking statements contained in this press release represent the company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, the company explicitly disclaims any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Trademarks Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation. SOURCE Blueprint Medicines Corporation